EU merger control

Notifiable concentration

If a transaction falls within the scope of the EU Mergers Regulation (EUMR), it will need to be notified to the European Commission and be cleared before the transaction can be completed. The Commission will investigate the transaction—if it has competition concerns, it can prohibit the transaction or accept remedies from the parties that address those concerns.

A transaction will fall within the EUMR and require notification to the Commission if:

  1. it is a ‘concentration’

  2. the transaction is permanent, and

  3. it meets the financial thresholds set out in the EUMR

The EUMR defines a ‘concentration’ as follows:

  1. where two independent businesses merge

  2. the acquisition of control by one (or more) business over another, either

    1. one business gaining ‘sole control’ over the target business

    2. two or more businesses gaining ‘joint control’ over the target business

  3. where there is a change of control in the acquired business, or

  4. where a full-function joint venture is formed (see Practice Note: EU merger rules—joint ventures)

For further information on ‘concentration’ and the financial thresholds, see Practice Notes:

  1. A

To view the latest version of this document and thousands of others like it, sign-in with LexisNexis or register for a free trial.

Powered by Lexis+®
Latest EU Law News

MedTech Europe leads industry call for EU to provide medical device regulatory relief by early 2026

MedTech Europe, together with 35 national associations, has urged the European Commission to take swift action on regulatory challenges affecting the medical device and diagnostic sectors. While EU officials are already collecting evidence to support future reforms of the medical device and in vitro diagnostic regulations, which are meant to simplify and improve efficiency, the signatories of the open letter argue that immediate relief is also essential. They call for a combination of short-term measures alongside longer-term legislative reforms. In particular, the letter asks for an implementing act to standardize the work of notified bodies, pilot projects for regulatory pathways covering orphan, pediatric, and breakthrough devices, and a targeted delay of re-certification requirements for certain products. According to MedTech Europe, harmonizing rules for notified bodies would help reduce duplication, speed up assessments, and ease the overall regulatory burden. The proposed postponement of re-certification deadlines is seen as necessary to avoid bottlenecks that could disrupt the supply of devices ahead of 2028. Looking further ahead, the associations want amendments to both MDR and IVDR that reflect the specific needs of each sector, alongside the creation of a single governance structure to oversee notified bodies and the CE-marking system, which they consider vital to the future of European medical technology regulation.

View EU Law by content type :

Popular documents